Anika Therapeutics (ANIK) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue was $41.9 million, down 5% year-over-year, mainly due to U.S. OA Pain Management softness, partially offset by international growth and new product launches like Integrity.

• Adjusted EBITDA margin reached 15% for the quarter, with adjusted EBITDA of $6.3 million, reflecting cost savings and business refocus initiatives.

• Net loss narrowed to $0.1 million from $2.7 million last year; adjusted net income was $2.5 million.

• Full market release of the Integrity Implant System expanded the regenerative portfolio, with strong surgeon interest and over 300 cases completed.

• A $40 million share repurchase program was announced, with $1.4 million repurchased in Q2 and $3 million year-to-date.

Financial highlights

• OA Pain Management revenue fell 9% to $26.7 million, mainly due to lower U.S. sales; international OA Pain sales grew 17–19%.

• Joint Preservation and Restoration revenue rose 7% to $13.5 million, led by Integrity and X-Twist.

• Non-Orthopedic revenue declined 26% to $1.7 million.

• Gross margin was 65%; adjusted gross margin was 66%, down from 69% last year.

• Cash balance at quarter-end was $62.8 million, with no debt.

Outlook and guidance

• 2024 total revenue guidance maintained at $168–$173 million, representing 1–4% growth.

• OA Pain Management expected at $102–$104 million (flat to 2% growth); international sales strength to offset U.S. softness.

• Joint Preservation and Restoration projected at $58–$60.5 million, up 6–10% year-over-year.

• Non-Orthopedic revenue expected at $8–$8.5 million, down 14–19%.

• Adjusted EBITDA expected at the lower end of $25–$30 million, with a full-year margin of ~15%.